TY  - JOUR
AU  - Hammes, Jochen
AU  - Drzezga, Alexander
AU  - Eimeren, Thilo
TI  - The Role of Tau Imaging in Parkinsonian Disorders.
JO  - Current neurology and neuroscience reports
VL  - 18
IS  - 12
SN  - 1528-4042
CY  - Philadelphia, Pa.
PB  - Current Science Inc.
M1  - DZNE-2020-06578
SP  - 86
PY  - 2018
AB  - Differential diagnosis of atypical Parkinson syndromes (APS) is difficult as clinical presentations may vary and as there is a strong overlap between disease entities. Aggregations of misfolded and hyperphosphorylated tau proteins are the common denominator of many of these diseases.Several tau targeting positron emission tomography (PET) tracers have been evaluated as possible biomarkers in APS in the recent years. For Parkinson's disease, dementia with Lewy bodies, progressive supranuclear palsy, and corticobasal degeneration, promising results have been reported with regard to the ability to detect the presence of disease and to discriminate patients from controls. However, the discussion about the specificity of the first-generation radiotracers and their value in the clinical context is ongoing. A combined interpretation of signal strength and distribution pattern in PET scans with first- and second-generation tracers may be helpful in clinical diagnosis and follow-up of patients with APS.
KW  - Alzheimer Disease: diagnosis
KW  - Alzheimer Disease: diagnostic imaging
KW  - Alzheimer Disease: metabolism
KW  - Diagnosis, Differential
KW  - Humans
KW  - Parkinsonian Disorders: diagnostic imaging
KW  - Parkinsonian Disorders: metabolism
KW  - Positron-Emission Tomography: methods
KW  - Supranuclear Palsy, Progressive: diagnosis
KW  - Supranuclear Palsy, Progressive: diagnostic imaging
KW  - Supranuclear Palsy, Progressive: metabolism
KW  - tau Proteins: metabolism
KW  - tau Proteins (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:30293094
DO  - DOI:10.1007/s11910-018-0898-3
UR  - https://pub.dzne.de/record/140256
ER  -